When a Clinical Evaluation Report falls short of EU MDR requirements, teams face a choice between two substantially different workstreams: an update or a remediation. The difference matters for scoping, resource planning, and timeline — and getting it wrong in either direction creates problems. Underscoping a remediation leads to a document that still attracts Notified Body questions. Overscoping an update wastes time on a structural rebuild that was not necessary.

What is a CER update?

A CER update assumes that the existing document's structure, scope, and clinical evidence logic are fundamentally sound. The update incorporates new post-market data, adds recent literature, reflects any changes to the intended purpose or device design, and refreshes the benefit-risk analysis to confirm it still holds.

Updates are appropriate when:

  • The CER was written or last substantially revised under EU MDR (not MDD)
  • No significant evidence gaps were identified at the last review
  • No Notified Body comments are outstanding on the clinical evaluation
  • The intended purpose and device design have not changed materially
  • New PMS and PMCF data is available but does not alter the benefit-risk conclusions

What is a CER remediation?

A remediation addresses structural or content deficiencies that prevent the existing document from meeting MDR requirements. This goes beyond adding new data — it involves reconsidering the evaluation framework, rebuilding the SOTA or clinical evidence sections, and in many cases rewriting the benefit-risk logic from the ground up.

Remediations are appropriate when:

  • The CER was written under MDD and has not been substantially restructured for MDR
  • The document lacks a Clinical Evaluation Plan or has no explicit SOTA methodology
  • Notified Body comments have identified evidence gaps or structural problems
  • Benefit-risk conclusions cannot be traced to specific clinical data in the document
  • The document needs to be extended to cover a new indication or device variant
  • Post-market data has materially changed the benefit-risk picture

How to decide: scope the gaps first

The most reliable way to determine which workstream applies is a structured gap assessment against MEDDEV 2.7/1 revision 4 and EU MDR Annex XIV. This maps the existing document section by section, identifies what is missing or weak, and — critically — distinguishes between gaps that can be filled within the existing structure and gaps that require the structure to change.

As a rough guide: if more than 40% of the CER's clinical content needs to be rewritten, or if the evaluation plan or SOTA methodology does not exist, a remediation is almost always the more efficient path. Attempting to update a structurally deficient document section by section usually takes longer than remediating it properly.

Timeline and resource implications

A well-scoped CER update for a Class IIb device typically takes four to eight weeks from access to documentation to delivery of a reviewed draft, depending on the volume of new PMS/PMCF data and literature. A remediation for the same device class typically takes eight to sixteen weeks, reflecting the additional time required to establish the evaluation framework and rebuild the SOTA.

For teams with active Notified Body correspondence, timeline is not always discretionary. Remediation work that is responsive to specific NB comments needs to be planned against the response deadline, with the scope of revisions agreed with the Notified Body where possible before writing begins.

Starting with a gap review

Before committing to either a full update or a remediation, a targeted gap review of the existing CER — typically a half-day to one-day assessment — gives you the information needed to scope the work accurately. It identifies the specific sections that need attention, the evidence gaps that carry the most review risk, and the clearest path to an MDR-compliant document.